A phase II study of topical ceramides for cutaneous breast cancer

Breast Cancer Research and Treatment

Volumn 80, Issue 1, 2003, Pages 99-104

  Jatoi, Aminah ^a   Suman, Vera J ^a   Schaefer, Paul ^a   Block, Margaret ^b   Loprinzi, Charles ^a   Roche, Patrick ^a   Garneau, Stuart ^c   Morton, Roscoe ^d   Stella, Philip J ^e   Alberts, Steven R ^a   Pittelkow, Mark ^a   Sloan, Jeff ^a   Pagano, Richard ^a  

^a MAYO CLINIC   (United States)

^b MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^c Cedar Rapids Oncology Project CCOP   (United States)

^d Oncology Research Association CCOP   (United States)

^e Ann Arbor Regional CCOP   (United States)

Author keywords

Apoptosis; Ceramides; Clinical trial; Cutaneous cancer; Quality of life

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CERAMIDE DERIVATIVE;

ADULT; AGED; ANEMIA; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; HUMAN; LIVER DYSFUNCTION; MULTICENTER STUDY; NAUSEA; NICK END LABELING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RASH; SKIN BIOPSY; SKIN METASTASIS; STOMATITIS;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CERAMIDES; FEMALE; HUMANS; IN SITU NICK-END LABELING; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 0038160944     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024409123726     Document Type: Article

References (22)

1. Shimozuma K, Sonoo H, Ichihara K, et al.: Analysis of the factors influencing quality of life of patients with advanced or recurrent breast cancer. Jpn J Surg 25: 874-882, 1995
2. Lookingbill DP, Pangler N, Helm KF, et al.: Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 29: 228-236, 1993
3. Terwogt JMM, Mandjes IAM, Sindermann H, et al.: Phase II trial with topically applied miltefosine solution in patients with skin-metastasized breast cancer. Br J Cancer 79: 1158-1161, 1999
4. Leonard R, Hardy J, van Tienhoven G, et al.: Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol 19: 4150-4159, 2001
5. Smorenburg CH, Seynaeve C, Bontenbal M, et al.: Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anticancer Drugs 11: 825-828, 2000
6. Clive S, Leonard RC: Miltefosine in recurrent cutaneous breast cancer. Lancet 349: 621-622, 1997
7. Jarvis WD, Grant S, Kolesnick RN. et al.: Ceramide and the induction of apoptosis. Clin Cancer Res 2: 1-6, 1996
8. Herr I, Wilhelm D, Bohler T, et al.: Activation of CD95 signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 16: 6200-6208, 1997
9. Dobrowsky RT, Hannun YA: Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem 267: 5048-5051, 1992
10. Dobrowsky RT, Kamibayishi C, Mumby MC, et al.: Ceramide activates a heterotrimeric protein phosphatase A2. J Biol Chem 268: 15523-15530, 1993
11. Wolff RA, Dobrowsky TR, Bielawska A, et al.: Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J Biol Chem 269: 19609-19609, 1994
12. Lozano J, Berra E, Muncio MM, et al.: Protein kinase C is critical for NF kappa B dependent promotor activation by sphingomyelinase. J Biol Chem 269: 19200-19202, 1994
13. Muller G, Ayoub M, Storz P, et al.: Protein kinase C is a molecular switch in signal transduction of TNF alpha, bifunctionally regulated by ceramide and arachadonic acid. EMBO J 14: 1961-1969, 1995
14. Mathias S, Younes A, Kan C, et al.: Activation of the sphingomyelin signaling pathway in intact EL4 cells and in cell-free system by IL-1 beta. Science 259: 519-522, 1993
15. Joseph CK, Byun HS, Bittman R, et al.: Substrate recognition by ceramide-activated protein kinase: evidence that kinase activity is protein-directed. J Biol Chem 268: 20002-20006, 1993
16. Liu J, Mathias S, Yang Z, et al.: Renaturation and TNF alpha stimulation of a 97-kDa ceramide-activated protein kinase. J Biol Chem 269: 3047-3052, 1994
17. Gulbins E, Coggeshall M, Baier G, et al.: Direct stimulation of vav guanine nucleotide exchange activity for ras by phorbal diesters and diglyceride. Mol Cell Biol 14: 4749-4758, 1994
18. Verheij M, Bose R, Lin XH, et al.: Requirement for ceramide-initiated stress-activated protein kinase/c-jun aminoterminal kinase signaling in stress-induced apoptosis. Nature 380: 75-79, 1996
19. Westick JK, Bielawska ARE, Dbaibo GS, et al.: Ceramide activates the stress-activated protein kinases. J Biol Chem 270: 22689-22692, 1995
20. Lopez-Marure R, Guitierrez G, Mendoza C, et al.: Ceramide promotes the death of human cervical tumor cells in the absence of biochemical and morphological markers of apoptosis. Biochem Biophys Res Commun 10: 1028-1036, 2002
21. Maru M, Haraguchi M, Higashi H, et al.: Anti-tumor activity of ceramides and glycosphingolipids in a murine tumor system. Int J Cancer 53: 645-650, 1993
22. Pagano RE, Sleight RG.: Defining lipid transport pathways in animal cells. Science 229: 1051-1057, 1985